Serial Measurement of Amino-Terminal Pro-B-Type Natriuretic Peptide Predicts Adverse Cardiovascular Outcome in Children With Primary Myocardial Dysfunction and Acute Decompensated Heart Failure

• Published in: Pediatric critical care medicine Vol. 16; no. 6; p. 529
• Main Authors: Medar, Shivanand Shankar, Hsu, Daphne T, Ushay, H Michael, Lamour, Jacqueline M, Cohen, Hillel W, Killinger, James S
• Format: Journal Article
• Language: English
• Published: United States 01.07.2015
• Subjects: Acute Disease; Adolescent; Child; Child, Preschool; Extracorporeal Membrane Oxygenation; Female; Follow-Up Studies; Heart Failure - blood; Heart Failure - mortality; Heart Transplantation; Heart-Assist Devices; Humans; Male; Natriuretic Peptide, Brain - blood; Peptide Fragments - blood; Predictive Value of Tests; Prospective Studies; ROC Curve; Ventricular Dysfunction - blood
• ISSN: 1529-7535
• DOI: 10.1097/PCC.0000000000000408

In children, elevated amino-terminal pro-B-type natriuretic peptide levels are associated with impaired heart function. The predictive value of serial monitoring of amino-terminal pro-B-type natriuretic peptide levels in acute decompensated heart failure is unclear. Prospective observational study. Single, tertiary referral pediatric critical care unit. Patients aged 0-21 years with primary myocardial dysfunction and acute decompensated heart failure. Amino-terminal pro-B-type natriuretic peptide levels were obtained on enrollment, day 2, and day 7. Clinical, laboratory, and imaging data were collected on enrollment. Adverse cardiovascular outcome was defined as heart transplant, ventricular assist device placement, extracorporeal membrane oxygenation, or death at 1 year after admission. Aminoterminal pro-B-type natriuretic peptide levels and the percent change from day 0 to day 2 and day 0 to day 7 were calculated and compared between those with and without adverse cardiovascular outcome. Sixteen consecutive patients were enrolled. Adverse cardiovascular outcome occurred in six patients (37.5%, four heart transplant and two ventricular assist device). In patients with an adverse cardiovascular outcome, median amino-terminal pro-B-type natriuretic peptide levels at day 7 were significantly higher (7,365 vs 1,196 pg/mL; p = 0.02) and the percent decline in amino-terminal pro-B-type natriuretic peptide was significantly smaller (28% vs 73%; p = 0.02) compared with those without an adverse cardiovascular outcome. Receiver operating curve analysis revealed that a less than 55% decline in amino-terminal pro-B-type natriuretic peptide levels at day 7 had a sensitivity and specificity of 83% and 90%, respectively, in predicting an adverse cardiovascular (area under the curve, 0.86; 95% CI, 0.68-1.0; p = 0.02). In conclusion, children with primary myocardial dysfunction and acute decompensated heart failure, a persistently elevated amino-terminal pro-B-type natriuretic peptide, and/or a lesser degree of decline in amino-terminal pro-B-type natriuretic peptide during the first week of presentation were strongly associated with adverse cardiovascular outcome. Serial amino-terminal pro-B-type natriuretic peptide monitoring may allow the early identification of children at risk for worse outcome.